Calliditas Therapeutics AB (CALT) Fundamental Analysis & Valuation

NASDAQ:CALT • US13124Q1067

Current stock price

40.0001 USD
-0.16 (-0.4%)
Last:

This CALT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CALT Profitability Analysis

1.1 Basic Checks

  • In the past year CALT has reported negative net income.
  • CALT had a negative operating cash flow in the past year.
  • In the past 5 years CALT always reported negative net income.
  • CALT had a negative operating cash flow in each of the past 5 years.
CALT Yearly Net Income VS EBIT VS OCF VS FCFCALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

  • The Return On Assets of CALT (-27.49%) is comparable to the rest of the industry.
  • CALT has a Return On Equity of -449.82%. This is amonst the worse of the industry: CALT underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -27.49%
ROE -449.82%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
CALT Yearly ROA, ROE, ROICCALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

  • Looking at the Gross Margin, with a value of 93.46%, CALT belongs to the top of the industry, outperforming 96.41% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for CALT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALT Yearly Profit, Operating, Gross MarginsCALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CALT Health Analysis

2.1 Basic Checks

  • CALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CALT has about the same amount of shares outstanding.
  • The debt/assets ratio for CALT is higher compared to a year ago.
CALT Yearly Shares OutstandingCALT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CALT Yearly Total Debt VS Total AssetsCALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

  • A Debt/Equity ratio of 9.44 is on the high side and indicates that CALT has dependencies on debt financing.
  • The Debt to Equity ratio of CALT (9.44) is worse than 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.44
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.73%
CALT Yearly LT Debt VS Equity VS FCFCALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.69 indicates that CALT has no problem at all paying its short term obligations.
  • CALT's Current ratio of 2.69 is in line compared to the rest of the industry. CALT outperforms 44.62% of its industry peers.
  • A Quick Ratio of 2.59 indicates that CALT has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.59, CALT perfoms like the industry average, outperforming 48.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.59
CALT Yearly Current Assets VS Current LiabilitesCALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CALT Growth Analysis

3.1 Past

  • CALT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.52%.
  • CALT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.27%.
  • CALT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 1013.57% yearly.
EPS 1Y (TTM)-64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.54%
Revenue 1Y (TTM)39.27%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Sales Q2Q%107.8%

3.2 Future

  • CALT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 78.56% yearly.
  • CALT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.98% yearly.
EPS Next Y127%
EPS Next 2Y105.23%
EPS Next 3Y87.75%
EPS Next 5Y78.56%
Revenue Next Year70.05%
Revenue Next 2Y66.46%
Revenue Next 3Y58.16%
Revenue Next 5Y39.98%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CALT Yearly Revenue VS EstimatesCALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
CALT Yearly EPS VS EstimatesCALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100 150 200 250

More info and screens

Find the best growth stocksShow best growing peers

4

4. CALT Valuation Analysis

4.1 Price/Earnings Ratio

  • CALT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • CALT is valuated reasonably with a Price/Forward Earnings ratio of 10.59.
  • 87.69% of the companies in the same industry are more expensive than CALT, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.05, CALT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 10.59
CALT Price Earnings VS Forward Price EarningsCALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALT Per share dataCALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • CALT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as CALT's earnings are expected to grow with 87.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y105.23%
EPS Next 3Y87.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CALT Dividend Analysis

5.1 Amount

  • CALT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CALT Fundamentals: All Metrics, Ratios and Statistics

Calliditas Therapeutics AB

NASDAQ:CALT (9/20/2024, 8:00:02 PM)

40.0001

-0.16 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13
Earnings (Next)11-11
Inst Owners0.08%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.08B
Revenue(TTM)1.60B
Net Income(TTM)-480.36M
Analysts81.54
Price Target45.37 (13.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-176.69%
Min EPS beat(2)-181.66%
Max EPS beat(2)-171.73%
EPS beat(4)1
Avg EPS beat(4)-312.91%
Min EPS beat(4)-979.13%
Max EPS beat(4)80.89%
EPS beat(8)4
Avg EPS beat(8)-142.18%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.01%
Min Revenue beat(2)-22.04%
Max Revenue beat(2)22.03%
Revenue beat(4)2
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-22.04%
Max Revenue beat(4)23.96%
Revenue beat(8)4
Avg Revenue beat(8)20.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.89%
PT rev (3m)6.52%
EPS NQ rev (1m)-0.67%
EPS NQ rev (3m)61.18%
EPS NY rev (1m)-0.67%
EPS NY rev (3m)-20.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.59
P/S 6.82
P/FCF N/A
P/OCF N/A
P/B 102.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)3.78
Fwd EY9.44%
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS5.87
BVpS0.39
TBVpS-1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.49%
ROE -449.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.46%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-22.62%
ROE(3y)-80.89%
ROE(5y)-56.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 9.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.59
Altman-Z N/A
F-Score2
WACC6.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.54%
EPS Next Y127%
EPS Next 2Y105.23%
EPS Next 3Y87.75%
EPS Next 5Y78.56%
Revenue 1Y (TTM)39.27%
Revenue growth 3Y1013.57%
Revenue growth 5YN/A
Sales Q2Q%107.8%
Revenue Next Year70.05%
Revenue Next 2Y66.46%
Revenue Next 3Y58.16%
Revenue Next 5Y39.98%
EBIT growth 1Y-36.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.93%
EBIT Next 3Y83.96%
EBIT Next 5Y69.01%
FCF growth 1Y59.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.92%
OCF growth 3YN/A
OCF growth 5YN/A

Calliditas Therapeutics AB / CALT Fundamental Analysis FAQ

What is the fundamental rating for CALT stock?

ChartMill assigns a fundamental rating of 3 / 10 to CALT.


What is the valuation status of Calliditas Therapeutics AB (CALT) stock?

ChartMill assigns a valuation rating of 4 / 10 to Calliditas Therapeutics AB (CALT). This can be considered as Fairly Valued.


What is the profitability of CALT stock?

Calliditas Therapeutics AB (CALT) has a profitability rating of 1 / 10.


Can you provide the financial health for CALT stock?

The financial health rating of Calliditas Therapeutics AB (CALT) is 3 / 10.